Efeitos da administração de probiótico Bifidobacterium animalis subsp. lactis HN019 na progressão da periodontite experimental em ratos submetidos a quimioterapia

Abstract

Chemotherapy increases the severity of periodontitis and compromises the outcome of periodontal treatment. Probiotics have emerged as an alternative for the treatment of pathologies, modulating the immune response of the host and modifying the bacterial environment. The objective of the present study was to evaluate the effects of probiotic administration (PROB) Bifidobacterium animalis subsp. lactis HN019 in the progression of experimental periodontitis (EP) in rats submitted to chemotherapy (5-fluorouracil-5-FU). Eighty male rats were divided into the following groups: control (C); treatment with 5-FU alone (5FU) (60 mg / kg on the day of EP induction and 40 mg / kg 48h after); treatment with PROB alone (HN019) (daily for 44 days, starting 30 before induction of EP); treatment with 5-FU and PROB (5FU-HN019); only EP (ligation in the lower first molars, maintained for 14 days); EP and treatment with 5-FU (EP-5FU); EP and treatment with PROB (EP-HN019); and EP and treatment with 5-FU and PROB (EP-5FU-HN019). All animals were euthanized 44 days after the beginnig of the experiment and the hemi-mandibles were processed for histomorphometric, microtomographic and immunohistochemical analysis. The analyzes revealed greater loss of bone and connective tissue in the EP-5FU group compared to the EP-5FU-HN019 group. And the immunohistochemical analysis showed a decrease in immunoblotting for TRAP and RANKL and increase for OPG in the EP-5FU-HN019 group, when compared to the group EP-5FU. PROB HN019 promoted a protective effect against bone loss and conjunctive insertion resulting from experimental periodontitis in immunosuppressed animals.